A series of substituted oxopropanylindole hydrazone derivatives was synthesized and evaluated for anti-oxidant and anti-dyslipidemic activity. Among these 12 compounds the three compounds 6c, 7b and 7d showed good anti-oxidant activity and the compound 6c attenuataed LDL oxidation by 32%. The compounds 6c and 7d also showed good anti-dyslipidemic activity by reducing serum levels of total cholesterol (TC), phospholipids (PL) and triglycerides (TG).
INTRODUCTION
Atherosclerosis is a key contributor in the cardiovascular diseases (CVDs) which are the major cause of mortality around the world. According to WHO, by 2030 more than 23 million people will die annually from CVDs [1] . These are multifactorial diseases. Diseases like obesity, diabetes mellitus, impaired glucose tolerance, insulin resistance, dyslipidemia (high LDL cholesterol, low HDL cholesterol, and high triglyceride levels in blood), and increased blood pressure raise the risk of cardiovascular diseases [2] .
The involvement of oxidative stress in combination with hyperlipidemia in the pathogenesis and development of atherosclerosis as well as type 2 diabetes has recently been reported [3] . There is growing evidence that hydroxyl free radicals are involved as major factor causing peroxidative damage to lipoproteins present in the blood, which are responsible for the onset and advancement of atherosclerosis [4] . Moreover, in hyperglycemic patients, the occurrence of several nonenzymatic glycosylations is accompanied by glucose oxidation catalyzed by Cu2+ and Fe2+ resulting in the formation of O2-and OH• radicals which further accelerates the risk of cardiac diseases in dyslipidemic patients [5] . treatment with extraction, fractionation and the test compounds were given same amount of gum acacia suspension (vehicle). After 18 hours of treatment the animals were anaesthetized with thiopentone solution (50 mg/kg b.w.) prepared in normal saline and 1ml blood was withdrawn from retro-orbital sinus using glass capillary in EDTA coated tubes (3.0 mg/ml blood). The blood was centrifuged at 2500 x g for 10 minutes at 4ºC and plasma was separated. Plasma was diluted with normal saline (ratio of 1:3) and used for analysis of total cholesterol (TC), Phospholipid (PL) and triglyceride (TG) by standard enzymatic methods. Using Beckmann autoanalyzer and standard kit purchase from Merck Company and post-heparin lipolytic activity (PHLA) was assayed using spectrophotometer [19] .
Lipoprotein measurement
Plasma was fractionated into very low-density lipoprotein (VLDL), low density lipoprotein (LDL) and high-density lipoprotein (HDL) by poly anionic precipitation methods. Lipoproteins were analyzed for their triglyceride (TG) level by standard procedures reported earlier [20] .
Lipoprotein lipase activity in liver of triton induced hyperlipidemic rats
Liver was homogenized (10%, w/v) in cold 100 mM phosphate buffer pH 7.2 and used for the assay of total lipolytic activity of lipoprotein lipase (LPL) [18] .
Molecular modeling
Human lipoprotein lipase (Uniprot Seq: P06858) plausible structural model was built using the single template of horse lipoprotein lipase protein (PDB ID: 1HPL) using Swiss model server.
Sequence identity between Human and horse lipoprotein lipase protein is around ~30 % which makes is good candidate for template selection [21] . Homology model was inspected to ensure that the side chains of the conserved residues were aligned to the template. The outlier residues were examined using the Ramachandran plot and the refined using Prime module of Schrodinger software package. Protein and ligands were prepared using default protocol implemented in Schrodinger software package [22] . Compounds were subjected to the InducedFit docking algorithm of the Schrodinger software package where the amino acid residues of proteins were also allowed to move freely along with docked ligand. The receptor grid (LPL binding site) was defined as reported previously [23] . The lowest energy conformation among the largest populated cluster sharing common interactions was selected as the best binding pose for docked ligands.
Cell culture and adipogenic differentiation
3T3-L1 mouse embryo fibroblasts cell line was obtained from the American Type Culture Collection. Cells were cultured in a humidified atmosphere at 37ºC and 5% CO2 in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) heat-inactivated fetal bovine serum and antibiotic penicillin and streptomycin. For adipogenesis induction 50000 cells were seed in 24 multi-well plates. After 2 days, when cells achieved nearcomplete confluence, culture media was replaced with adipogenesis media I (containing Insulin 5 µg/ml, IBMX 0.5 mM and Dexamethasone 250 nm in culture medium). This media was then replaced after 72 hours with adipogenesis media II (Insulin 5 µg/ml in DMEM with 10% FBS). After replacement of this media, cells were then maintained next 2 days in 10% FBS containing DMEM medium. Lipid globules in the adipogenic cells starts forming from day 4th onwards after treatment, and fully developed adipocytes were observed after day 8th of adipogenesis treatment. More than 80% cells do have lipid globules at this stage.
Triglyceride assay and Oil Red O staining
To study effect of compound on adipogenic differentiation, cells were differentiated as 
Anti-hyperglycemic activity
Male albino rats of Sprague-Dawley strain (8 to 10 weeks of age body weight 160 ± 20 g)
were selected for this study. Streptozotocin (Sigma, USA) was dissolved 100 mM citrate buffer The blood glucose level of each animal was determined just before the administration of standard drug and test samples (0 min) and thereafter at 30, 60, 90, 120, 180, 240, 300 and 1440 min.
Food but not water was withdrawn from the cages during 0 to 300 min. The average lowering in blood glucose level between 0 to 300 min and 0 to 1440 min was calculated by plotting the blood glucose level on y-axis and time on x-axis and determining the area under curve (AUC).
Comparing the AUC of experimental group with that to control group determined the percent lowering of blood glucose level during the period. Statistical analysis was made by Dunnett's test (Prism Software).
Statistical evaluation
All results are presented as the means ± S.D. of results from three independent experiments.
Groups were analyzed via t-tests (two-sided) or ANOVA for experiments with more than two subgroups. Probability values of p < 0.05 were statistically significant
Results and Discussion

Anti-oxidant activity
Anti-oxidant activity of test compounds were evaluated by measuring the scavenging potential at 200 µg/ml against formation of O2and OH • in non-enzymatic systems listed in Table 1 . Further, the effect of compounds on lipid peroxidation in microsomes were also studied. Out of total 12 compounds screened three compounds 6c, 7b, and 7d showed significant decrease in superoxide anions (33%, 27%, and 25%) as compared to the standard drug allopurinol which showed 43%
inhibition of superoxide anions. The compounds 6c, 7b, and 7d also reduced hydroxyl radicals by 35%, 29%, and 23% respectively in comparison to mannitol which showed 47% inhibition in hydroxyl radicals.
Furthermore, the effect of these compounds on the nonenzymatic peroxidation of microsomal membrane lipids was also studied. The compounds 6c, 7b, and 7d at 200 µg /ml reduced the microsomal lipid per-oxidation by 35%, 26%, and 23% respectively as compared to αtocopherol with 50% inhibition 
LDL oxidation activity
The cascade of cellular processes can lead to the formation of fatty streaks and ultimately atherosclerotic lesions in the arterial wall as it is triggered by oxidative modification of LDL, so the compounds 6c, 7b, and 7d were also examined for their anti-oxidant activities on human LDL oxidation induced by cupric ions (CuSO4). Aerobic oxidation of LDL even in the absence of metal ions caused formation of TBARS (nmol MDA/mg protein), which were greatly increased by 10 to 15 folds in the presence of Cu +2 . Addition of compounds 6c, 7b, and 7d at 200 µg/ml concentrations in above reaction mixture attenuated LDL oxidation by 32%, 24%, and 
In vivo anti-dyslipidemic activity
The in vivo anti-dyslipidemic activity of these derivatives was also evaluated in triton induced hyperlipidemic model based on the reduction of experimentally induced elevated plasma lipid and MDA levels All the compounds reduced the examined parameters in the plasma of hyperlipidemic rats however, compounds 6c and 7d (100 mg/kg b.w) improved the serum lipoproteins TG level in triton induced hyperlipidemic rats by 26% and 24% respectively. The analysis of hyperlipidemic serum of triton administered rats showed significant increase in the level of VLDL-TG and LDL-TG followed by decrease in HDL-TG as compared to control rats. 
Lipoprotein lipase activity of active compounds
Lipoprotein lipase (LPL) is a major enzyme in overall lipid metabolism and transport, being responsible for hydrolysis of triglycerides present in circulating lipoproteins [27, 28] Decreased adipose tissue LPL activity related to the hypertriglyceridaemia condition which in turn associated with insulin resistance and type II diabetes [29] .Therefore, the effect of active compounds 6c and 7d were further evaluated for lipoprotein lipase activity (LPLA) in triton induced hyperlipidemic rats. Administration of triton in rats markedly decreases in LPL activity in liver. 
Effect of compound 6c and 7d on 3T3-L1 cells
Excessive accumulation of adipose mass tissue not only contributes to obesity but also increase the risk of cardiovascular disease and type-2 diabetes. Therefore, the active compounds of the series 6c and 7d were also evaluated on 3T3-L1 preadipocytes. To investigate the antiadipogenic effect of compound 6c and 7d, cells were treated with and without MDI adipogenic media and 20µM of compound 6c and 7d dissolved in MDI adipogenic media (MDI is adipogenic media with IBMX, dexamethosone and Insulin used to differentiate preadipocytes into adipocytes). Adipogenesis was assessed by oil red O (ORO) staining of lipid droplets. ORO staining results showed that Compound 6c and 7d reduced MDI mediated lipid accumulation at 20µM as observed microscopically ( Figure 4A ). MDI-induced greater lipid accumulation was reduced approximately 44% and 31% in the cells treated with compound 6c and 7d at 20µM, as measured spectrophotmetrically ( Figure 4B ). 
In vivo Anti-hyperglycemic activity
Taking into consideration the promising anti-oxidant, anti-dyslipidemic and anti-adepogenic activity of compound 6c and 7d, these compounds were further tested for their anti-diabetic activity. Figure 5a .
Conclusion
In summary, a series of 12 substituted hydrazone derivatives were synthesized and evaluated for the anti-oxidant, anti-dyslipidemic activity in an acute triton induced hyperlipidemic model.
Among the 12 compounds two compounds 6c and 7d showed good anti-oxidant activity with enhanced protection against lipid peroxidation. Both the compounds 6c and 7d also showed effective protection against LDL oxidation and reduced the TC and TG levels by 23-26% with improved lipoprotein lipase activity corroborated by the binding energies of these compounds at lipoprotein lipase binding site. Molecular docking study also suggested important role of Thr-238 to the ligand binding at lipoprotein lipase active site. Both the compounds 6c and 7d also showed anti-adipogenic and anti-hyperglycemic activity, where compound 6c was found to be the most active compound with 44% reduction in lipid accumulation and also reduce the blood glucose by 20.5% at 5h and 24.3% at 24h in comparison to standard drug metformin. Thus, these compounds with balanced activities may be useful in the treatment of metabolic disorder.
Characterization details
Chemistry
Melting points were determined on an electrical heated m. p. apparatus /using silicon oil bath.
Reactions were monitored by thin layer chromatography on self-made plates of silica gel G (Merck, India) or 0.25mm ready-made plates of silica gel 60F254, (Merck, Darmstadt, Germany). Column chromatography was performed on silica gel (Merck, 60 to 120mesh).
Infrared spectra (IR) were recorded on Perkin-FTIR model PC spectrophotometer with frequency of absorptions reported in wave numbers. MS were recorded on JEOL spectrometer with fragmentation pattern reported as values. 1H NMR was recorded on Bruker spectrometer with a multinuclear inverse probe head with gradient at room temperature (298 K) using CDCl3 as solvent and tetramethylsilane (TMS) as internal standard. Chemical shifts were described in parts per million (ppm) relative to TMS (0.00 ppm) using scale, and coupling constants were reported in hertz (Hz).
Synthesis of DL-tryptophan methyl ester hydrochloride
Thionyl chloride (7ml) was added drop wise to a stirred suspension of DL-tryptophan 1 (10g) in dry methanol (45 ml) at -10°C during 30 min and stirring continued for 6 hrs during which temperature was gradually raised from -10°C to room temperature (25°C). The reaction mixture 
Synthesis of DL-N-benzoyl tryptophan methylester (2)
Benzoyl chloride (1.15ml) in dry THF (5ml) was added to a stirred solution of dl tryptophan methyl ester (1) (2.18gm, 1eq) and dry triethylamine (1.66 ml, 1.2eq) in dry THF (8ml) during 15 min and was allowed to stir for 2 hrs at room temperature. The reaction mixture was concentrated under vacuum; the residue was triturated with water (20 ml) to get 2b, which was Compounds 3-4 were synthesized in the same manner.
Synthesis of (DL)-N-(1-hydrazinyl-3-(1H-indol-3-yl)-1-oxopropan-2-yl) benzamide (5)
A solution of 2b (1.7 g, 5.5 mmol) in ethanol (20 mL) containing 85% hydrazine hydrate (10 mL) was refluxed for 6 h. The reaction mixture was concentrated under vacuum, to give white solid which was triturated with water and dried to give compound 5, which was further Compounds 6-7were synthesized in the same manner.
Synthesis of N-(1-(2-( 4-chlorobenzylidene) hydrazinyl)-3-(1H-indol-3-yl)-1oxopropan-2-yl)benzamide (5a)
Equimolar quantities of hydrazide (5) N-(3-(1H-indol-3-yl)-1-(2-(4-methylbenzylidene ) N-(1-(2-(4-chlorobenzylidene) 1.9. N-(3-(1H-indol-3-yl)-1-(2-(4-methoxybenzylidene) N-(1-(2-(4-chlorobenzylidene) 
